EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhanced Cerebroprotection of Xenon-Loaded Liposomes in Combination with rtPA Thrombolysis for Embolic Ischemic Stroke

Tao Peng, Keith Booher, Melanie R Moody iD, Xing Yin iD, Jaroslaw Aronowski, David D McPherson, Sean I Savitz, Hyunggun Kim iD, Shao-Ling Huang

Biomolecules · 2023

DOI: 10.3390/biom13081256 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Tao Peng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houst…. Hauptthemen laut MEDLINE: Ischemic Stroke, Stroke, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Xenon (Xe) has shown great potential as a stroke treatment due to its exceptional ability to protect brain tissue without inducing side effects. We have previously developed Xe-loaded liposomes for the ultrasound-activated delivery of Xe into the cerebral region and demonstrated their therapeutic efficacy. At present, the sole FDA-approved thrombolytic agent for stroke treatment is recombinant tissue plasminogen activator (rtPA). In this study, we aimed to investigate the potential of combining Xe-liposomes with an intravenous rtPA treatment in a clinically relevant embolic rat stroke model. We evaluated the combinational effect using an in vitro clot lysis model and an in vivo embolic middle cerebral artery occlusion (eMCAO) rat model. The treatment groups received intravenous administration of Xe-liposomes (20 mg/kg) at 2 h post-stroke onset, followed by the administration of rtPA (10 mg/kg) at either 2 or 4 h after the onset. Three days after the stroke, behavioral tests were conducted, and brain sections were collected for triphenyltetrazolium chloride (TTC) and TUNEL staining. Infarct size was determined as normalized infarct volume (%). Both in vitro and in vivo clot lysis experiments demonstrated that Xe-liposomes in combination with rtPA resulted in effective clot lysis comparable to the treatment with free rtPA alone. Animals treated with Xe-liposomes in combination with rtPA showed reduced TUNEL-positive cells and demonstrated improved neurological recovery. Importantly, Xe-liposomes in combination with late rtPA treatment reduced rtPA-induced hemorrhage, attributing to the reduction of MMP9 immunoreactivity. This study demonstrates that the combined therapy of Xe-liposomes and rtPA provides enhanced therapeutic efficacy, leading to decreased neuronal cell death and a potential to mitigate hemorrhagic side effects associated with late rtPA treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ischemic StrokeStrokeDrug-Related Side Effects and Adverse ReactionsAnimalsRatsTissue Plasminogen ActivatorLiposomesFibrinolytic AgentsInfarctionThrombolytic Therapy

Stichwörter der Autor:innen

cerebroprotectiveembolic ischemic strokeliposometissue plasminogen activatorxenon

Substanzen

Tissue Plasminogen ActivatorLiposomesFibrinolytic Agents

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
  • Zymo Research Corporation, Irvine, CA 92614, USA.
  • Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
  • Institute for Stroke and Cerebrovascular Disease, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
  • Department of Biomechatronic Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea.

ORCID-Profile: Melanie R Moody, Xing Yin, Hyunggun Kim

Förderung

  • NINDS NIH HHS
  • National Institutes of Health

Zitieren

APA

Peng, T., Booher, K., Moody, M. R., Yin, X., Aronowski, J., McPherson, D. D., Savitz, S. I., Kim, H., & Huang, S. L. (2023). Enhanced Cerebroprotection of Xenon-Loaded Liposomes in Combination with rtPA Thrombolysis for Embolic Ischemic Stroke. Biomolecules. https://doi.org/10.3390/biom13081256

Vancouver

Peng T, Booher K, Moody MR, Yin X, Aronowski J, McPherson DD, et al. Enhanced Cerebroprotection of Xenon-Loaded Liposomes in Combination with rtPA Thrombolysis for Embolic Ischemic Stroke. Biomolecules. 2023. doi:10.3390/biom13081256

BibTeX
@article{Peng2023,
  author = {Peng, Tao and Booher, Keith and Moody, Melanie R and Yin, Xing and Aronowski, Jaroslaw and McPherson, David D and Savitz, Sean I and Kim, Hyunggun and Huang, Shao-Ling},
  title = {Enhanced Cerebroprotection of Xenon-Loaded Liposomes in Combination with rtPA Thrombolysis for Embolic Ischemic Stroke},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13081256}
}
Kostenlos starten →